Fig. 3From: Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trialMixed-effects model analysis of EuroQoL Five-Dimension VAS. CI confidence interval, VAS visual analogue scaleBack to article page